Home/Pipeline/TCR-based T-cell Engagers

TCR-based T-cell Engagers

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Triplebar

About Triplebar

Triplebar is a private, pre-revenue biotech platform company leveraging a proprietary combination of AI and microfluidics to engineer biological solutions at unprecedented speed and scale. The company's core technology enables the high-throughput screening of billions of genetic variants to generate application-specific datasets and develop products across therapeutics, food, and agriculture. With a seasoned leadership team and strategic partnerships, Triplebar is positioned to disrupt traditional bio-engineering, though it faces significant competition and technical execution risks in a capital-intensive sector.

View full company profile

Therapeutic Areas

Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active